Treatment Guided by Comprehensive Genomic Profiling and Expert MTB Decision-Making Improves Outcomes in Pretreated Patients with Metastatic Cancer By Ogkologos - October 14, 2025 370 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the ROME study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR Adjuvant Nivolumab Prolongs DFS in Patients with Resected Osophageal or Gastroesophageal... April 6, 2021 Aromatase inhibitors cut breast cancer recurrence in younger patients February 11, 2022 Perioperative Enfortumab Vedotin Plus Pembrolizumab Improves EFS, OS and pCR in... February 23, 2026 EMA Recommends Granting a Marketing Authorisation for Ripretinib for the Treatment... October 5, 2021 Load more HOT NEWS Development of T-Cell Lymphoma After Chimeric Antigen Receptor T-Cell Therapy For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Preparing for your COVID-19 Vaccine: What to Ask your Provider Talquetamab Continues To Demonstrate High Overall Response Rates in Heavily Pretreated...
